A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.

Inclusion Criteria

• •Sign the informed consent form before starting any trial related procedure.
• •18-80 years old, male or female.
• •Non-small cell lung cancer confirmed by cytology or histology. Evaluation by the researchers to confirm resectable stage IIB, IIIA or resectable stage IIIB (CT3-4N2M0) NSCLC patients without any treatment before.
• •If the pathological type is adenocarcinoma, genetic testing is required.
• •Newly treated patients or patients with failure of traditional preoperative neoadjuvant chemotherapy can be enrolled;
• •ECOG PS 0-1.
• •Good cardiac function, left ventricular ejection fraction \>50%;
• •Good respiratory function, able to tolerate radical resection of lung cancer;
• •Bone marrow hematopoietic function is good, leukocyte\> 4×10\^9/l; Hemoglobin\> 10g/dl; Platelet \> 100×10\^9/l;
• •Good renal function, glomerular filtration rate\>60 ml/min.
• •Good liver function, Total bilirubin(TBIL)\<1.5ULN, AST\<2.5 ULN, ALT\<3ULN;
• •There must be at least one evaluable focus judged according to recist1.1 standard.